We treated PR3-ANCA positive vasculitis patient with bilateral ischemic peroneal nerve paralysis accompanying rheumatoid arthritis. Pathology showed mild vasculitis. With PR3-ANCA amelioration, the level of complement 3, anti-CCP and neurological disability normalized simultaneously responding to rituximab. This result means the shared pathogenic pathway of PR3-ANCA vasculitis and rheumatoid arthritis.